NEW YORK, May 8, 2020 /PRNewswire/ --
URGENT: STOCKHOLDER VOTE MAY 19,
2020
WeissLaw LLP is investigating possible breaches of
fiduciary duty and other violations of law by the board of
directors of Assertio Therapeutics, Inc. ("Assertio" or the
"Company") (NASDAQ: ASRT) in connection with the proposed merger of
the Company with Zyla Life Sciences ("Zyla"). Under the terms
of the proposed merger, (i) Zyla stockholders will be entitled to
receive 2.5 shares of common stock of a newly-formed holding
company for each share of Zyla common stock currently held, (ii)
the newly combined company will retain the Assertio name, and (iii)
Assertio stockholders are expected to own 68% of the new company,
with Zyla stockholders owning the remaining 32%.
If you own shares and wish to discuss this
investigation or have any questions concerning this notice or your
rights or interests, visit our website:
http://www.weisslawllp.com/assertio-therapeutics-inc/
Or please contact:
Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY 10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com
WeissLaw is investigating whether the Company's board acted in
the best interests of its stockholders by entering into the merger
agreement. Although Assertio stockholders will control 68% of
the newly-formed combined entity, it is unclear from the
April 20, 2020 Definitive Proxy filed
with the Securities and Exchange Commission whether the relative
values of Assertio and Zyla warrant the dilution of the Company's
stockholders' interests that will result from the consummation of
the deal. Among other deficiencies, the Definitive Proxy
fails to provide critical projected financial information necessary
for Assertio stockholders to fully and fairly evaluate the merits
of the proposed merger.
Given these facts, WeissLaw is concerned whether the proposed
acquisition is in the best interests of Assertio stockholders, and
whether all material information related to the proposed
acquisition is fully and fairly disclosed.
WeissLaw LLP has litigated hundreds of stockholder class and
derivative actions for violations of corporate and fiduciary
duties. We have recovered over a billion dollars for
defrauded clients and obtained important corporate governance
relief in many of these cases. If you have information or
would like legal advice concerning possible corporate wrongdoing
(including insider trading, waste of corporate assets, accounting
fraud, or materially misleading information), consumer fraud
(including false advertising, defective products, or other
deceptive business practices), or anti-trust violations, please
email us at stockinfo@weisslawllp.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-assertio-therapeutics-inc-301056047.html
SOURCE WeissLaw LLP